Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS

Data continue to demonstrate prolonged durability of response, with median duration of CR reaching 16.1 months in frontline HR‑MDS, supporting the upcoming initiation of the Phase 2b trialMedian duration of Complete Remission (CR) in treatment-naïve …